Please login to the form below

Not currently logged in

AstraZeneca to present new oncology data at AACR

The American Association for Cancer Research Annual Meeting takes place in New Orleans from 8-13 April 2022


AstraZeneca (AZ) will present new data highlighting the capabilities of its early oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, which is taking place from 8-13 April 2022.

It will include data from 60 presentations – including five oral and three mini-oral presentations – and will feature AZ’s next phase of potential cancer treatments covering its immuno-oncology (IO), DNA Damage Response (DDR) and Antibody Drug Conjugate (ADC) scientific platforms.

Data will be shared from three potential new medicines that highlight AZ’s approach to molecular design which addresses key complex challenges in treating cancer – including the ability to target different, complementary mechanisms.

The company will be introducing its next wave of IO therapies, sharing the first clinical results for MEDI5752 – a novel bispecific antibody, which simultaneously targets immune checkpoint proteins  in solid tumours. Bispecific antibodies are a promising IO approach, combining the potential benefits of two treatments in one.

A presentation from the NeoCOAST phase 2 trial in resectable, early-stage non-small cell lung cancer is planned to highlight improved disease responses with Imfinzi (durvalumab) combinations, including with oleclumab and monalizumab, as compared to Imfinzi alone.

As part of AZ’s focus on building the next generation of PARP inhibitors, the first data will be presented from the PETRA phase 1 clinical trial in patients with tumours harbouring specific homologous recombination repair gene mutations.

Additionally, four presentations will describe the discovery of a novel selective inhibitor designed to cross the blood brain barrier to enable the targeting of primary and secondary brain malignancies.

Article by
Fleur Jeffries

30th March 2022

From: Research



Subscribe to our email news alerts


Add my company

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....